Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials

Research output: Contribution to journalComment/debateResearchpeer-review

Original languageEnglish
JournalJournal of Internal Medicine
Volume295
Issue number5
Pages (from-to)707-710
ISSN0954-6820
DOIs
Publication statusPublished - 2024

    Research areas

  • coronary disease, lipids, myocardial infarction, stroke, triglycerides-rich lipoproteins, very low-density lipoproteins

ID: 383885109